Clinical Trials Logo

Filter by:
NCT ID: NCT05542641 Recruiting - Healthy Cognition Clinical Trials

T-mult: Exploring the Impact of TMS Induced Virtual Lesions on the Multimodal Brain Network and Cognition

Start date: April 25, 2023
Phase: N/A
Study type: Interventional

T-mult is an experimental study using low-frequency (1Hz) single-sesson rTMS to the DLPFC (versus sham rTMS) to explore the effect of virtual lesions on the brain network and cognition in 100 healthy adults (20-65 years old).

NCT ID: NCT05541978 Completed - Multiple Myeloma Clinical Trials

Thrombosis in Patients With Multiple Myeloma in an University Medical Center

THRIMM
Start date: September 1, 2022
Phase:
Study type: Observational

Main research question: What is the present venous thrombosis incidence and what are the current practices of prescribing thromboprophylaxis in patients with multiple myeloma (MM)? Design: The present study is a retrospective cohort study. The patients will be selected from the electronic patient dossier (EPD) of the University Medical Center Groningen (UMCG). The present study will include newly diagnosed adult patients with a first MM at the UMCG between 1st of January 2014 and 1st of September 2021. The primary outcome of the study is the incidence of venous thromboembolism (VTE) with one year of diagnosis of MM. The investigators will also describe the various thromboprophylaxis regimens used and their corresponding VTE incidence. The secondary outcome will be the incidence of arterial thrombosis (AT) within the same period of time. Possible confounders are the therapy administered for MM, thromboprophylaxis type, age and patient comorbidities. Lastly, the third outcome will be a description of current thromboprophylaxis practices in the UMCG. Each outcome will be described separately. Expected results: Based on the study by de Waal et al in which they included 474 MM patients treated at the UMCG and at 4 hospitals in the province Friesland, the investigators expect to record a VTE incidence of approximately 15%.

NCT ID: NCT05541263 Recruiting - Stress Clinical Trials

Mindful Network Dynamics Regulation Under Stress

MindRest
Start date: March 1, 2021
Phase: N/A
Study type: Interventional

This study aims to assess the effectiveness of Mindfulness Based Stress reduction to reduce perceived stress in a highly stressed student population, while concurrently investigating neural mechanisms of the intervention. The investigators will perform a randomized, wait-list controlled trial assessing clinical and neurocognitive outcomes as well as measures of daily life stress reactivity.

NCT ID: NCT05540444 Completed - Communication Clinical Trials

RadConnect Communication Application

RadConnect
Start date: September 29, 2022
Phase:
Study type: Observational

The aim is to evaluate the impact of an innovative asynchronous communication application on the number of calls from technologists to radiologists. Even though it is paramount that radiologists be accessible and available to other healthcare workers in the enterprise, frequent interruptions have negative impact on productivity and well-being. A novel communication app was developed that streamlines communication between technologists and radiologists: RadConnect.

NCT ID: NCT05540197 Enrolling by invitation - Diabetes Mellitus Clinical Trials

Arginine-stimulated Indication of Early Outcome After Islet Transplantation

ALADDIN
Start date: February 23, 2023
Phase:
Study type: Observational

Through islet transplantation, functional β-cell mass can be restored. Allogeneic islet transplantation is a treatment modality for a select group of patients with complicated type 1 diabetes mellitus. For patients undergoing (partial) pancreas resection, autologous islet transplantation may help prevent complicated diabetes. Up until now, no studies have been performed on early islet graft function in the first week after transplantation. Early graft function may be a predictor for estimating long-term islet graft success. Arginine can excite β-cells to release insulin. It can thus provide an estimate of β-cell secretory capacity and can be used as an alternative to (oral) glucose tolerance tests. In this study, we aim to find a predictor model for islet graft function by assessing peak C-peptide after arginine stimulus in the early post-transplantation phase.

NCT ID: NCT05539300 Recruiting - Prostate Cancer Clinical Trials

PSMA Response in Metastasized Hormone Sensitive Prostate Cancer - Enzalutamide

PET-MaN-enza
Start date: March 1, 2023
Phase: N/A
Study type: Interventional

PSMA-PET/CT response measurements after LHRH agonist and upfront enzalutamide therapy in men diagnosed with de novo metastasized hormonal sensitive prostate cancer.

NCT ID: NCT05539170 Recruiting - Parenting Clinical Trials

Parents' Differential Susceptibility to Microtrial

Start date: November 1, 2022
Phase: N/A
Study type: Interventional

This randomized controlled microtrial, not just focus on parental (and child) responsiveness but also on an underlying physiological mechanism hypothesized to contribute to heightened susceptibility to parenting interventions.

NCT ID: NCT05538806 Recruiting - Clinical trials for Pleural Mesothelioma

TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study

TIGER Meso
Start date: August 1, 2023
Phase:
Study type: Observational

The purpose of this post-authorisation medical device study is to obtain real life data on the use of Tumor Treating Fields (TTFields) in patients with pleural mesothelioma in routine clinical care. Patients with pleural mesothelioma and clinical indication for TTFields treatment will be enrolled in the study after signing Informed consent to use their data and process it centrally for research purposes. The clinical indication for TTFields is one of the inclusion criteria and is defined prior to inclusion by the treating physician.

NCT ID: NCT05538416 Recruiting - Clinical trials for Degenerative Spondylolisthesis

Short-term Clinical Outcome of Cortical Bone Trajectory Compared With the Traditional "Open" and Minimal Invasive Posterior Lumbar Interbody Fusion

Start date: September 19, 2022
Phase:
Study type: Observational

A combined prospective cohort study and retrospective analysis of previously collected data. Three different techniques for posterior lumbar interbody fusion (PLIF) are compared: CBT-PLIF, MI-PLIF and open PLIF. A total of 180 patients are included, who will be followed up to 6 weeks postoperatively.

NCT ID: NCT05537766 Recruiting - Clinical trials for Relapsed/Refractory Hairy Cell Leukemia

Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies

ZUMA-25
Start date: November 1, 2022
Phase: Phase 2
Study type: Interventional

Master protocol: The goal of this master clinical study is to test how well the study drug, brexucabtagene autoleucel, works in participants with rare B-cell malignancies: relapsed/refractory Waldenstrom macroglobulinemia (r/r WM) (Substudy A - no longer recruiting), relapsed/refractory Richter transformation (r/r RT) (Substudy B), relapsed/refractory Burkitt lymphoma (r/r BL) (Substudy C and relapsed/refractory hairy cell leukemia (r/r HCL) (Substudy D - no longer recruiting).